Osaka, Japan - August 17, 2020 - Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) received approvals by the Ministry of Health, Labour and Welfare for 4 generic drugs with 13 strengths. The 2 compounds marked with an asterisk below are approved for the first time as generics.
The list of approved products
1. Pregabalin OD Tablets, Capsules
|Strengths||OD Tablets, Capsules: 25 mg, 75 mg, 150 mg|
|Brand products||Lyrica® OD Tablets 25 mg, 75 mg, 150 mg,
Lyrica® Capsules 25 mg, 75 mg, 150 mg
2. Rivastigmine Tapes
|Strengths||4.5 mg, 9 mg, 13.5 mg, 18 mg|
|Brand products||EXELON® PATCH 4.5 mg, 9 mg, 13.5 mg, 18 mg,
RIVASTACH® Patches 4.5 mg, 9 mg, 13.5 mg, 18 mg
3. Bortezomib for Injection
|Brand products||VELCADE® Injection 3 mg|
4. Famotidine Intravenous Injection
|Strengths||10 mg, 20 mg|
|Brand products||Gaster® Injection 10 mg, 20 mg|
The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.